These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 11370497)

  • 1. An organ-preserving approach to muscle-invading transitional cell cancer of the bladder.
    Brown AL; Zietman AL; Shipley WU; Kaufman DS
    Hematol Oncol Clin North Am; 2001 Apr; 15(2):345-58, vii. PubMed ID: 11370497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A bladder cancer multi-institutional experience with total cystectomy for muscle-invasive bladder cancer.
    Scher HI
    J Urol; 1994 Aug; 152(2 Pt 1):574-5. PubMed ID: 8015114
    [No Abstract]   [Full Text] [Related]  

  • 3. Selective organ preservation for the treatment of muscle-invasive transitional cell carcinoma of the bladder: a review of current and future perspectives.
    Hafeez S; Huddart R
    Expert Rev Anticancer Ther; 2014 Dec; 14(12):1429-43. PubMed ID: 25263197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bladder preserving approach for muscle invasive bladder cancer--role of mycobacterium w.
    Chaudhuri P; Mukhopadhyay S
    J Indian Med Assoc; 2003 Sep; 101(9):559-60. PubMed ID: 15168998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Muscle-invasive bladder tumour: can the bladder be preserved?
    Sella A
    BJU Int; 2008 Nov; 102(9):1053-4. PubMed ID: 18715247
    [No Abstract]   [Full Text] [Related]  

  • 6. Muscle-invasive bladder cancer organ-preserving therapy: systematic review and meta-analysis.
    García-Perdomo HA; Montes-Cardona CE; Guacheta M; Castillo DF; Reis LO
    World J Urol; 2018 Dec; 36(12):1997-2008. PubMed ID: 29943218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Invasive bladder cancer--where do we go from here?
    Waters WB
    J Urol; 1996 Jun; 155(6):1910-1. PubMed ID: 8618285
    [No Abstract]   [Full Text] [Related]  

  • 8. [Therapy and follow-up of bladder cancer].
    Meyer D; Schmid HP; Engeler DS
    Wien Med Wochenschr; 2007; 157(7-8):162-9. PubMed ID: 17492413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trimodality therapy for bladder conservation in treatment of invasive bladder cancer.
    Mitin T; Shipley WU; Efstathiou JA; Heney NM; Kaufman DS; Lee RJ; Zietman AL
    Curr Urol Rep; 2013 Apr; 14(2):109-15. PubMed ID: 23341373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Organ-sparing treatment of bladder cancer].
    Niedworok C; Shaleva A; Rübben H; Stenzl A
    Urologe A; 2016 May; 55(5):609-14. PubMed ID: 27119956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder.
    Zietman AL; Grocela J; Zehr E; Kaufman DS; Young RH; Althausen AF; Heney NM; Shipley WU
    Urology; 2001 Sep; 58(3):380-5. PubMed ID: 11549485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selection of treatment for muscle infiltrating transitional cell bladder cancer.
    Whitmore WF
    Arch Esp Urol; 1990; 43 Suppl 2():219-22. PubMed ID: 2096783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of high-risk non-muscle invasive bladder cancer.
    Brausi M; Olaru V
    Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [pT1G3 bladder carcinoma: our experience].
    Dell'Orto P; Trinchieri A; D'Addezio F; Bernardini P; Mangiarotti B; Del Nero A; Pisani E
    Arch Ital Urol Androl; 1996 Feb; 68(1):9-11. PubMed ID: 8664927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of combined method in organ-sparing treatment of muscle-invasive bladder cancer recurrences.
    Startsev VY
    Arch Ital Urol Androl; 2002 Jun; 74(2):54-6. PubMed ID: 12161935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An organ-sparing treatment using combined intra-arterial chemotherapy and radiotherapy for muscle-invading bladder carcinoma.
    Tsukamoto S; Ishikawa S; Tsutsumi M; Nakajima K; Sugahara S
    Scand J Urol Nephrol; 2002; 36(5):339-43. PubMed ID: 12487737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T1G3: What to do?
    Mandressi A
    Arch Ital Urol Androl; 1996 Feb; 68(1):5-7. PubMed ID: 8664922
    [No Abstract]   [Full Text] [Related]  

  • 18. [pT1G3 bladder carcinoma: parameters of a correct therapy].
    Ruoppolo M; Dell'Orto P; Fenice O; Seveso M; Ferri P; Zaatar C; Tagliaferri A; Cogni M; Bellorofonte G; Tombolini P
    Arch Ital Urol Androl; 1996 Feb; 68(1):17-20. PubMed ID: 8664914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative analysis of the effect of prostatic invasion patterns on cancer-specific mortality after radical cystectomy in pT4a urothelial carcinoma of the bladder.
    Vallo S; Gilfrich C; Burger M; Volkmer B; Boehm K; Rink M; Chun FK; Roghmann F; Novotny V; Mani J; Brisuda A; Mayr R; Stredele R; Noldus J; Schnabel M; May M; Fritsche HM; Pycha A; Martini T; Wirth M; Roigas J; Bastian PJ; Nuhn P; Dahlem R; Haferkamp A; Fisch M; Aziz A
    Urol Oncol; 2016 Oct; 34(10):432.e1-8. PubMed ID: 27283218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of muscle invasive bladder cancer in the elderly: navigating the trade-offs of risk and benefit.
    VanderWalde NA; Chi MT; Hurria A; Galsky MD; Nielsen ME
    World J Urol; 2016 Jan; 34(1):3-11. PubMed ID: 26497825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.